Pulsethera

Raising $4 million to build new phototherapy for skin decolonization and drug resistant infection treatment

Facebook Twitter LinkedIn

Founded by Harvard Medical School and Boston University Professors, Pulsethera (www.pulsethera.com) provides phototherapy platform for universal patient decolonization in hospitals and drug resistant microbes infection treatment. We have received NIH funding for our research. We have obtained 2 US patents expect patents in Asia and Europa. We have engaged medical device expert to help us start FDA Q-submission and plan to start device filing work early next month. We expect revenue more than $100 million for our patient skin decolonization in three years, and revenue close to $100 million for our wound treatment  device in two years after we received our medical license expected in year 2025.

We are now looking to raise capital for our FDA medical device filing work and future business development.

•Unmet need: treating infections without concern for antimicrobial resistance 
•Technology: inactivate microbes’ defenses against reactive oxygen species (“ROS”) 
•Supporting data: in vitro and in vivo microbe killing studies
•Intellectual property: 2 issued US patents and 9 pending international and US patent applications
•FDA Interactions:  2022 Q4 Q-Submission for skin decontamination 
•US market creation/revenues (2024 to 2027): $215 million
 
 

Ready to Ask For Funding for your company?

Post a Funding Request

Pulsethera is no longer seeking funding.